Insufficient screening for heart damage after noncardiac surgery puts patients at risk

December 10, 2020

Philadelphia, December 10, 2020 - About five percent of patients experience heart muscle injury around the time of their surgery for a noncardiac condition, yet guideline recommendations to identify patients at risk using biomarkers are not being followed. A five-year , published by Elsevier, determined that the recommended biomarker screening is very much underutilized.

Of the 1.5 million Canadians who undergo inpatient noncardiac surgery each year, 22,000-45,000 will experience a perioperative cardiac event. For this reason, guidelines now recommend that patients with risk factors for heart disease have cardiac enzyme measurements done after their surgery, even if they do not have any symptoms.

"Although surgical and anesthetic advancements and more effective treatments for heart damage have resulted in fewer people dying around the time of surgery, perioperative cardiovascular complications remain an important concern," explained lead investigator Michelle M. Graham, MD, University of Alberta, Division of Cardiology and Mazankowski Alberta Heart Institute, Edmonton, AB, Canada.

Without biomarker screening, asymptomatic cardiac events may not be picked up for prompt treatment, which could lead to complications and excess deaths. "Many of these events are silent, meaning that patients will not experience any chest pain alerting their doctors that they are experiencing heart damage. For most of these patients, the only way that we would identify this is by measuring cardiac enzymes in their blood released by damaged heart cells," Dr. Graham added.

Evidence of the utility of biomarkers for perioperative screening began to emerge following the results of the 2011 Perioperative Ischemic Evaluation (POISE) study. In response to this growing evidence, multiple national and international guidelines for noncardiac surgery now recommend perioperative cardiac biomarker screening in high-risk patients. The Canadian Cardiovascular Society (CCS) published its Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery in 2017.

Using linked provincial administrative databases, investigators in Dr. Graham's study looked at the records of more than 300,000 patients in Alberta who had undergone noncardiac surgery from January 2013 to December 2017. They found that roughly one in five surgical patients, or 59,506, had risk factors for heart disease. Of these higher risk patients, only around seven percent underwent preoperative screening for the natriuretic peptide biomarker. Natriuretic peptides, which were originally used to diagnosis heart failure, now play an increasing role in identifying patients most at risk of cardiovascular disorders.

Patients with elevated perioperative screening biomarkers demonstrated increased six-month mortality, increased hospitalizations for heart failure, and acute coronary syndromes.

Investigators concluded that the use of biomarkers to assist in cardiac risk stratification and postoperative monitoring remains low, and they recommend addressing access to these tests and improving physician education regarding the asymptomatic nature of postoperative cardiac events to improve compliance with national guidelines.

"Now that we know that testing for heart damage after surgery is low, the medical community needs to be sensitized to this need and find out what we can do to improve it," noted Dr. Graham. "Improvement is going to require multispecialty cooperation among surgeons, cardiologists, other specialists, and family physicians. Further research is still required, but the first step is to actually identify these patients, closely monitor them, and aggressively treat their risk factors for heart disease."

In an accompanying


Related Biomarkers Articles from Brightsurf:

Urgent need for blood-based biomarkers to diagnosis concussion
There is an urgent need for objective markers for diagnosing concussion, or mild traumatic brain injury.

Engineered bacteria churn out cancer biomarkers
A Cornell lab has created these very tools by commandeering simple, single-celled microorganisms - namely E. coli bacteria - and engineering them to explore the complex process of glycosylation and the functional role that protein-linked glycans play in health and disease.

Exercise induces secretion of biomarkers into sweat
The aim was to reveal the potential of microRNAs in sweat extracellular vesicles in monitoring exercise performance.

Phosphoprotein biomarkers to guide cancer therapy are identified
Researchers led by James Bibb, Ph.D., professor of surgery at the University of Alabama at Birmingham, suggest using a broader lens of post-translational modification analysis to identify new biomarkers of cancer drivers that may allow a much more precise prediction of patient responses to treatments.

Exhaled biomarkers can reveal lung disease
Using specialized nanoparticles, MIT engineers have developed a way to diagnose pneumonia or other lung diseases by analyzing the breath exhaled by the patient.

Race-specific lupus nephritis biomarkers
A University of Houston biomedical researcher has discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

Semen miRNAs could be non-invasive biomarkers for prostate cancer
Researchers of the Human Molecular Genetics group at the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr.

Scientists have found longevity biomarkers
An international group of scientists studied the effects of 17 different lifespan-extending interventions on gene activity in mice and discovered genetic biomarkers of longevity.

After concussion, biomarkers in the blood may help predict recovery time
A study of high school and college football players suggests that biomarkers in the blood may have potential use in identifying which players are more likely to need a longer recovery time after concussion, according to a study published in the July 3, 2019, online issue of Neurology, the medical journal of the American Academy of Neurology.

3D-printed device detects biomarkers of preterm birth
Preterm birth (PTB) -- defined as birth before the 37th week of gestation -- is the leading complication of pregnancy.

Read More: Biomarkers News and Biomarkers Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to